SOURCE: annual_report_text (1).txt
CHUNK: 816 of 1106
SIZE: 622 characters
PREVIOUS: chunk_0815_annual_report_text (1).txt
NEXT: chunk_0817_annual_report_text (1).txt
------------------------------
in Normandy 
Hadrontherapy SAS remained at 39.81 % (no 
change from 2019) of this entity following 
financing by several public and private players. The objective of this project is to launch the 
development of the worlds first cyclotron-based 
carbon therapy system in Caen, France through 
its subsidiary Normandy Hadrontherapy (NHa), in collaboration with the Normandy Region and 
several other private and public players, including 
SAPHYN 
(SAnte 
et 
PHYsique 
Nucleaire). The overall investment by all partners in NHa is 
over EUR 60 million, in equity and bond 
financing 
(guaranteed 
by 
the 
Normandy 
Region).